Mastodon

Benoxi (Drops) Instructions for Use

Marketing Authorization Holder

Unimed Pharma, s.r.o. (Slovakia)

ATC Code

S01HA02 (Oxybuprocaine)

Active Substance

Oxybuprocaine (Rec.INN registered by WHO)

Dosage Form

Bottle Rx Icon Benoxi Eye drops 4 mg/1 ml: 10 ml dropper bottle

Dosage Form, Packaging, and Composition

Eye drops as a clear, colorless solution.

1 ml 1 bottle
Oxybuprocaine hydrochloride 4 mg 40 mg

Excipients: boric acid – 200 mg, chlorhexidine diacetate – 1 mg, purified water – up to 10 ml.

10 ml – plastic dropper bottles (1) – cardboard packs.

Clinical-Pharmacological Group

Local anesthetic for use in ophthalmology

Pharmacotherapeutic Group

Local anesthetic agent

Pharmacological Action

Local anesthetic for use in ophthalmology.

It causes a reversible block of the propagation and conduction of nerve impulses through the axons of nerve cells.

Pharmacokinetics

It is easily absorbed through the mucous membranes into the corneal stroma after a single instillation into the conjunctival sac.

Anesthesia occurs within 1-3 minutes.

During the subsequent 15 minutes, a quantitative decrease in the stromal concentration of oxybuprocaine is observed, which provides a 15-20 minute period of anesthesia after a single instillation.

Indications

Local anesthesia in ophthalmology (including superficial anesthesia of the cornea and conjunctiva) for tonometry, gonioscopy and other diagnostic examinations, before performing subconjunctival injections, for removal of foreign bodies and sutures from the cornea and conjunctiva, for short-term surgical interventions on the cornea and conjunctiva.

ICD codes

ICD-10 code Indication
Z51.4 Preparatory procedures for subsequent treatment or examination, not elsewhere classified
ICD-11 code Indication
QB9A Preparatory procedures for subsequent treatment

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Administer topically as instillations into the conjunctival sac.

For tonometry and other brief diagnostic procedures, instill 1-2 drops immediately prior to the examination.

For removal of corneal foreign bodies or sutures, instill 1-2 drops several minutes before the procedure. A second instillation may be required.

For short surgical interventions, instill 1 drop every 2-3 minutes for a total of 1-3 instillations.

Adjust the regimen based on the clinical situation and required duration of anesthesia.

Do not exceed the minimum number of drops necessary to achieve adequate anesthesia.

Avoid prolonged or repeated use beyond the immediate procedural requirement to prevent corneal complications.

Adverse Reactions

From the organ of vision: sensation of burning and conjunctival hyperemia, transient tingling sensation; damage to the corneal epithelial layer, keratitis and excoriation of the corneal surface.

Allergic reactions: anaphylactic shock.

From the CNS: grand mal epileptic seizure, fainting.

From the cardiovascular system: bradycardia.

Contraindications

Hypersensitivity to oxybuprocaine; children under 2 years of age.

With caution in patients with pseudocholinesterase deficiency, malignant myasthenia, and patients with epilepsy.

Use in Pregnancy and Lactation

The use of oxybuprocaine during pregnancy and breastfeeding is possible only in cases where the expected benefit of therapy for the mother outweighs the potential risk to the fetus or infant.

Pediatric Use

Contraindicated for use in children and adolescents under 2 years of age.

Special Precautions

The product is to be used only for instillation into the conjunctival sac.

Do not use for injections.

Prolonged, repeated and long-term use of oxybuprocaine (as well as other local anesthetics) may lead to persistent corneal clouding.

Oxybuprocaine is not intended for long-term therapy in complex eye disease.

During anesthesia, it is necessary to protect the eye from irritating chemical influences, foreign bodies and friction.

During treatment, alcohol consumption should be avoided.

Effect on the ability to drive vehicles and mechanisms

During treatment, patients should refrain from driving any vehicles and engaging in other activities that require high concentration and speed of psychomotor reactions.

Drug Interactions

Oxybuprocaine enhances the effect of succinylcholine and sympathomimetics, and reduces the effect of sulfonamides and beta-blockers.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS